therapeutically. Here, we describe a genetic rewiring of bacterial isoprenoid biosynthetic 23 pathways in the Rickettsiales that has resulted from reductive genome evolution. We 24 further investigated whether the spotted fever group Rickettsia species Rickettsia 25 parkeri scavenges isoprenoid precursors directly from the host. Using targeted mass 26 spectrometry in uninfected and infected cells, we found decreases in host isoprenoid 27 products and concomitant increases in bacterial isoprenoid metabolites. Additionally, we 28 report that bacterial growth is prohibited by inhibition of the host isoprenoid pathway 29 with the statins class of drugs. We show that growth inhibition correlates with changes 30 in bacterial size and shape that mimic those caused by antibiotics that inhibit 31 peptidoglycan biosynthesis, suggesting statins inhibit cell wall synthesis. Altogether, our 32 results describe an Achilles' heel of obligate intracellular pathogens that can be 33 exploited with host-targeted therapeutics that interfere with metabolic pathways required 34 for bacterial growth. Introduction isoprene precursor molecule, isopentenyl pyrophosphate (IPP), and its isomer, 78 dimethylallyl diphosphate (DMAPP), occurs through two distinct pathways. The 79 mevalonate (MEV) pathway (predominantly in archaea, Gram-positive bacteria, and 80 animals) or the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway (primarily in Gram-81 negative bacteria) ( Figure 1 ). In bacteria, isoprenoid biosynthesis produces vital 82 products such as bactoprenols (essential building blocks for peptidoglycan (PG) and 83 other cell wall polysaccharides), ubiquinone or menaquinone (involved in the electron 84 transport chain), or chlorophylls in cyanobacteria (10). In mammalian cells, isoprenoid 85 biosynthesis produces a larger variety of products including cholesterol, ubiquinone, 86 steroid hormones, prenylated proteins, heme, and vitamin K (11). 87
Although the isoprenoid biosynthetic pathway is essential, its components are 88 missing from certain obligate pathogens including Mycoplasma species (12) and the 89 protozoan parasite Cryptosporidium (13). Bioinformatic analysis (14) shows that genes 90 encoding the upstream enzymes from the MEV and MEP pathways that are required to 91 make IPP and DMAPP are also missing in Rickettsia species, with the exception of the 92 idi gene encoding the enzyme isopentenyl diphosphate isomerase (IDI), which 93 catalyzes the reversible conversion of IPP to DMAPP (15). Since Rickettsia have 94 access to metabolites in the host cytoplasm, this suggests that Rickettsia may steal IPP 95 and/or DMAPP, altering the flux of host-derived isoprenoid precursors to initiate 96 downstream bacterial isoprenoid biogenesis. The downstream enzymes required to 97 utilize these short-chained isoprenoid precursors for ubiquinone biosynthesis and PG 98 biosynthesis are encoded in Rickettsia genomes. 99
In this study, we explore the evolutionary changes that occurred within the order 100
Rickettsiales with respect to the presence of genes encoding components of the 101 isoprenoid biosynthetic pathway. We also show that bacterial infection results in 102 depletion of host isoprenoid products and the synthesis of bacterial isoprenoid products. 103
Furthermore, we use a chemical genetic approach to reveal that inhibition of host 104 isoprenoid biosynthesis by statin treatment prevents bacterial growth and alters 105 bacterial shape. Our results suggest that the host MEV pathway serves as the upstream 106 source of isoprene units for the synthesis of bacterial bactoprenols and ubiquinone, and 107 that inhibition of the host MEV pathway by statins may represent a promising avenue for 108 host-directed therapeutics to treat Rickettsia infection. 109
110

Results 111
The isoprenoid biosynthesis pathway is under evolutionary flux in the order 112
Rickettsiales 113
We first sought to determine the evolutionary conservation of the isoprenoid 114 biosynthesis pathway in the order Rickettsiales. We constructed a phylogenetic tree 115 using 16S rDNA sequences across six main genera of the order as well as the closest 116 free-living organism, Pelagibacter ubique, and assessed the presence or absence of 117 genes encoding upstream or downstream components of the MEP pathway as well as 118 the IDI enzyme ( Figure 2A ). We confirmed that the Rickettsia (14) and Orientia lineages 119 lack the genes encoding upstream MEP pathway enzymes but have those encoding the 120 downstream pathway components, whereas the other genera contained the full 121 complement of MEP pathway genes. None have MEV pathway genes, with the exception of the idi gene in Rickettsia species. The absence of upstream MEP pathway 123 genes suggests that Rickettsia must scavenge MEV/MEP pathway intermediates (IPP, 124 DMAPP or FPP, Figure 1 ) from the host cell. 125
Additionally, the idi gene is only present in the Rickettsia lineage but not the 126 Orientia lineage. A previous report suggested that the idi gene in Rickettsia was 127 acquired by horizontal gene transfer (14). To further investigate this, we examined the 128 genomic locus surrounding the idi gene in the R. parkeri str. Portsmouth genome 129 ( Figure 2B ). We found many surrounding genes that were associated with conjugal 130 transfer functions, such as transposases and pili. Furthermore, there are nine 131 surrounding pseudogenes with premature stop codons, suggesting this region is in flux 132 and may be in the process of undergoing genomic reduction. To further test this 133 hypothesis, we performed a whole genome alignment between R. parkeri and the 134
closely related yet more pathogenic species R. rickettsii. Interestingly, we found the two 135 genomes were highly syntenic, with the exception of a 65kb region containing the idi 136 gene ( Figure 2C , region in lime green, idi gene in purple) that is inverted between the 137 two species and in the R. rickettsii genome contains a 33.5 kb deletion (orange 138 highlighted region in Figure 2C and Supplemental Table S1 ). These observations 139 suggest that the locus surrounding the idi gene was acquired by horizontal gene 140 transfer and is still under evolutionary pressure to retain the idi gene while 141 simultaneously undergoing continuing reduction. 142 143
R. parkeri infection results in depletion of host isoprenoid products and 144 accumulation of bacterial isoprenoid products
To test whether R. parkeri scavenges host isoprenoids to make bacterial 146 products, we measured the presence and abundance of host and bacterial isoprenoid-147 derived metabolites by liquid chromatography-mass spectrometry (LC-MS/MS). For bacterial isoprenoids, we measured bactoprenols, which include the 159 isoprenoid products C55-isopentyl pyrophosphate (C55-IPP) and C55-isopentyl phosphate 160 (C55-IP). C55-IPP is initially produced by a dedicated prenyltransferase, UppS, and must 161 be dephosphorylated to C55-IP to act as a lipid carrier (17). We also measured bacterial 162 ubiquinone, ubiquinone-8, which contains an 8 prenyl subunit tail, in contrast with the 163 human version containing 10 prenyl subunits, ubiquinone-10 ( Figure 3 ) (18, 19). We 164 observed a statistically-significant approximately 4-fold increase in both C55-IPP and 165 C55-IP in infected compared with uninfected cells. We did not, however, find significant 166 differences in bacterial ubiquinone (ubiquinone-8), possibly due to the presence of 167 ubiquinone-8 intermediates from the host cell ubiquinone-10 biosynthesis pathway.
These results indicate that bacterial isoprenoid products, primarily bactoprenols, 169 accumulate during R. parkeri infection. Collectively, the depletion of host isoprenoid 170 products and accumulation of bacterial isoprenoid products, even in the absence of a 171 bacterial isoprenoid synthesis pathway, suggests that isoprenoids are scavenged from 172 the host by R. parkeri. 173 174
Chemical inhibition of the host mevalonate pathway inhibits bacterial growth 175
To determine whether host isoprenoids are necessary for bacterial growth, we 176 sought to inhibit the host mevalonate pathway and reduce the pool of available host IPP 177 and DMAPP. We used statins, a class of drugs that block the activity of HMG-CoA 178 reductase ( Figure 1) . A previous report showed that pre-incubation of R. conorii infected 179 mouse L929 fibroblast cells with the statin lovastatin caused a reduction in R. conorii 180 plaque size, which was interpreted to result from a reduction in cholesterol-dependent 181 adherence of bacteria to host cells (20). To bypass possible effects of statins on 182 bacterial adherence and invasion, we allowed infection of Vero cells to proceed for 2 h 183 to allow for maximal bacterial adherence/invasion (21), treated cells with (or without) 184 various concentrations of the statin pitavastatin, and then measured bacterial numbers 185 using a R. parkeri-specific qPCR endpoint assay ( Figure 4A ). We observed a >2-log 186 reduction in bacterial growth with increasing pitavastatin concentrations. To ensure that 187 statin inhibition of bacterial growth was dependent on HMG-CoA reductase inhibition by 188 pitavastatin and not secondary effects of the drug, we tested whether the downstream 189 product of HMG-CoA reductase, mevalonate, could rescue this growth inhibition.
Indeed, co-treated with 400 µM mevalonate along with pitavastatin rescued bacterial 191 growth ( Figure 4A ). 192
To further assess the importance of the MEV pathway, we generated dose-193 response curves for the effect of lovastatin and pitavastatin, which are chemically 194 distinct, on R. parkeri growth using a 96-well qPCR endpoint assay. We observed a 195 dose-dependent inhibition of bacterial growth with lovastatin (EC50 = 2.0 µM) and even 196 more robust inhibition with pitavastatin (EC50 = 0.5 µM) ( Figure 4B ). This data indicates 197 that the host MEV pathway is critical for R. parkeri growth. 198
To further test that bacterial growth is dependent on a complex integration of the 199 host and pathogen isoprenoid pathways (as depicted in Figure 1 ), we tested for dose-200 dependent growth inhibition using additional inhibitors of MEV and MEP pathway 201 enzymes ( Figure 4B ). Fosmidomycin, which specifically inhibits 1-deoxy-D-xylulose 5-202 phosphate (DXP) reductoisomerase, a key enzyme in the bacterial MEP pathway, 203 caused no inhibition of bacterial growth at up to 100 µM. Alendronate sodium, a specific 204 inhibitor of host farnesyl diphosphate (FPP) synthase, caused approximately 50% 205 growth inhibition. This further suggests that R. parkeri growth is independent of bacterial 206 isoprenoid production, and partially dependent on FPP from the host. 207
Finally, we tested the anti-bacterial antibiotics tetracycline, which is used as a one study showed that high concentrations of penicillin produced spheroplasts (27), a 227 type of L-form bacteria that have a defective PG cell wall and take on a spherical shape 228 (28). Therefore, we sought to measure whether statin inhibition of the host MEV 229 pathway altered bacterial shape in a similar manner to inhibition of PG synthesis. To 230 this end, we performed immunofluorescence microscopy on 96-well plates of infected 231 cells at 3 dpi to track the alterations of bacterial shape in response to dose-dependent 232 application of statins, D-cycloserine, or tetracycline as a control. We performed 233 automated image analysis using CellProfiler (29) and measured a number of bacterial 234 cell shape features. We determined that two shape measurements, area and 235 eccentricity (circle = 0, rod/line = 1), accounted for most of the shape alterations seen in the concentration ranges between EC50-EC100. In D-cycloserine treated cells, there was 237 a dose-dependent increase in area and decrease in eccentricity as bacteria became 238 more circular and less rod-shaped ( Figure 5A, B) . In cells treated with either lovastatin 239 or pitavastatin, similar changes in area and eccentricity were seen along the dose-240 response curve. In contrast, upon treatment with tetracycline, we found little change in 241 the bacterial area, although there was a general decrease in eccentricity. 242
Upon comparison of shapes at the EC100 of each drug compared to the no-drug-243 treated control, we observed a significant increase in bacterial area and significant 244 decrease in eccentricity in cells treated with D-cycloserine, lovastatin and pitavastatin 245 ( Figure 5C ). For tetracycline, we found no significant differences in area or eccentricity 246 Obligate intracellular pathogens such as Rickettsia are dependent upon nutrients 254 and metabolites from their host cells as a consequence of reductive genome evolution 255 (5, 6, 14). This suggests the possibility that this metabolic dependency represents an 256
Achilles' heel in the host-pathogen relationship, and that these pathogens could be 257 sensitive to changes in host cell nutrient and metabolite levels. If metabolite availability 258 is limited by the host or by extrinsic pressures such as chemical inhibition of a host biosynthetic pathway, pathogen growth should also be reduced. Here, we report the 260 reduction of R. parkeri replication when the host isoprenoid pathway is inhibited with 261 statins. This growth inhibition correlates with changes in bacterial shape that are 262 consistent with defects in cell wall biosynthesis. Our results suggest that statins interfere 263
with Rickettsia scavenging of host isoprenoids used for bacterial cell wall biosynthesis. Subsequently, the idi gene was gained in the Rickettsia lineage, which may reflect a 279 need for additional DMAPP beyond that acquired from the host MEV pathway. In 280 contrast, Ehrlichia, Anaplasma, Wolbachia, and Neorickettsia lineages, which grow within a membrane-bound vacuole, may not have sufficient access to host IPP and/or 282 DMAPP and therefore have retained the entire MEP pathway. 283
We also found evidence of metabolic parasitism of host isoprenoids by R. 284 parkeri. In particular, infected host cells become depleted of isoprenoid-derived storage 285 forms of cholesterol, total cholesteryl esters and choleteryl oleate, perhaps to balance 286 free cholesterol levels. Whether Rickettsia also scavenge downstream host isoprenoid 287 products such as cholesterol, as observed for other bacteria such as M. tuberculosis 288
and Chlamydia trachomatis (34-36), remains to be determined. Furthermore, R. parkeri 289 produces downstream isoprenoid products even though it lacks genes for the upstream 290 components of the MEP pathway. This metabolic parasitism suggests that inhibition of 291 host isoprenoid biosynthesis should reduce the ability of the bacteria to synthesize 292 bacterial isoprenoid products. 293
In keeping with this prediction, we found that statins, which inhibit host HMG-294
CoA-reductase, halt R. parkeri growth. Previous work had established an ability of 295 statins to limit rickettsial plaque size (20), but mechanism of inhibition was not explored 296 in detail. It was suggested that statins might inhibit Rickettsia adherence to and/or 297 invasion of host cells based on previous studies that had found a role for cholesterol 298 these processes (37, 38). Our work, however, reveals an effect of statins on intracellular 299 bacterial growth, downstream of adherence/invasion. Furthermore, with increasing 300 statin concentration, we find morphological changes in the shape and size of bacteria 301 that mirror those caused by the cell wall synthesis inhibitor D-cycloserine. These 302 observations lead us to conclude that statins inhibit bacterial growth by reducing host metabolite availability for production of bacterial products required for PG biosynthesis, 304 leading to lethal defects in the bacterial cell wall. 305
Whether statins can be effective at preventing or treating human Rickettsia 306 infections remains to be determined. Although statins are well tolerated in humans, and 307 both statins tested in this study are FDA-approved, we have limited understanding of 308 the dose response curves for inhibition of bacterial growth versus host toxicities that can 309 include myopathy and increased risk of diabetes and stroke (39). Furthermore, it is 310 unclear if statins have the same degree of bacterial growth inhibition in different 311 rickettsial target cell types in vivo. Additional studies in animal models will shed light on 312 future promise of statins as a prophylaxis or treatment for rickettsial infections. 313
Currently, cases of rickettsial diseases are effectively treated with tetracyclines, 314 although there are reported cases of tetracycline-resistant scrub typhus (40, 41) , and 315 tetracycline treatment is contraindicated for pregnant women and young children (42) . 316
Because a limited number of antibiotics are effective in treating rickettsial infections 317 (22), host-targeted therapeutics would be useful additions to treatment regimens. 318 Furthermore, targeting host biosynthesis of essential metabolites may limit the 319 development of antibiotic resistance. 320
Beyond the scope of rickettsial infections, this study points to a potential to use 321 host-targeted therapeutics for a wide variety of infectious microbes, including viruses, 322 bacteria, fungi, and parasites. Similar to R. parkeri, the parasite Cryptosporidium 323 parvum lacks the canonical protozoan isoprenoid pathway and has been shown to be 324 sensitive to statins (43). In the future, bioinformatic analyses may identify other 325 intracellular bacteria that have incomplete upstream isoprenoid pathways and intact downstream isoprenoid pathways, and thus may also be sensitive to statins. 327 Furthermore, Rickettsia and other parasites may be sensitive to chemical inhibition of 328 other host metabolic pathways. Layering our knowledge of FDA-approved compounds 329 that target host biosynthetic pathways onto predicted metabolic pathways hijacked by 330 pathogens may therefore enable the systematic identification of drug classes that could 331 be re-purposed as antibiotics. 
Mass spectrometry 377
Monolayers of Vero cells plated in 6-well plates were infected (or an uninfected control) 378 with R. parkeri as described above and were incubated for 4 d at a 33˚C 5% CO2. On 379 the day of harvest, cells in each well were washed with 4 ml of 1 x phosphate buffered 380 saline (PBS). 1 ml of fresh 1 x PBS was added to each well and used to scrape the 381 cells, centrifuged at 1000 x g for 5 min on a microfuge and the supernatant was 382 aspirated from the cell pellet. Cell pellets were extracted in 2:1:1 383 chloroform:methanol:PBS solution with addition of 10 nM dodecylglycerol internal 384 standard, after which the organic phase was separated, collected, and dried down 385 under N2 gas. The dried-down lipidome extract was then resuspended in 150 µl 386 chloroform and stored at -80˚C until analysis. For mass spectrometry analysis, an 387 aliquot of this sample solution was injected into an Agilent 6430 LC-MS/MS and 388 metabolites were chromatographically separated and analyzed by SRM-based targeted 389 LC-MS/MS as previously described (47, 48) . 390 391
Immunofluorescence microscopy 392
To measure bacterial shape, Vero cells were plated at 50% confluency on 96-393 well glass bottom plates in DMEM plus 2% FBS and allowed to settle overnight at 37˚C, 394 5% CO2. The following day, cells were infected with an MOI = 0.1 of wild-type R. parkeri, centrifuged at 300 x g for 5 min and incubated for 2 h at 33˚C, 5% CO2. Media 396 containing bacteria was aspirated and replaced with media with or without the 397 appropriate concentration of drug (see above), and cells were further incubated for 72 h 398 at 33˚C, 5% CO2. Cells were fixed with 4% paraformaldehyde in 1 x PBS for 20 min at 399 room temperature, washed with 1 x PBS, and permeabilized with 0.05% Triton X-100 in 400 1 x PBS for 5 min. Cells were then stained for immunofluorescence with mouse anti-401
Rickettsia primary antibody 14-13 and goat anti-mouse Alexa-488 secondary antibody 402 to stain bacteria, and Hoechst 33342 to stain DNA. Infected cells were imaged on a 403
Nikon Ti Eclipse microscope with a Yokogawa CSU-XI spinning disc confocal, 100X 404 
R. parkeri qPCR growth and drug dose response curves 412
Confluent Vero cells grown in 96-well tissue culture plates were infected with an MOI = 413 0.1 of R. parkeri and incubated in DMEM plus 2% FBS with or without the appropriate 414 concentration of drug (see above) for 72 h at 33˚C, 5% CO2. To harvest cells at the 415 appropriate time point, media was aspirated and cells lifted with 50 µl of 0.25% trypsin-416 EDTA followed by incubation at 37˚C for 5 min. Lifted cells were resuspended with an 417 additional 50 µl of DMEM before adding to 50 µl Nuclei Lysis Buffer (Wizard Genomic DNA Purification kit; Promega) and frozen at -20˚C overnight. Cells were then thawed 419 and boiled for 10 min to release genomic DNA. To remove RNA, 20 µg/mL RNAse A 420 was added to each sample, incubated for 15 min at 37˚C, and then samples were 421 cooled to room temperature. Protein was removed by adding 50 µl of protein 422 precipitation solution, mixing by pipetting, then centrifuging in a microfuge for 15 min at 
C.
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